ATM activation is accompanied with earlier stages of prostate tumorigenesis

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1763, Issue 10, 2006, Pages 1090-1097

  Fan, Catherine ^a,b   Quan, Rebecca ^b   Feng, Xinchang ^a   Gillis, Aubrey ^b   He, Lizhi ^a   Matsumoto, Edward D ^a   Salama, Sam ^a   Cutz, Jean Claude ^a   Kapoor, Anil ^a   Tang, Damu ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

Author keywords

H2AX; ATM; Chk2; p53; Prostate tumorigenesis

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; HISTONE H2AX; PROTEIN P53; SERINE; THREONINE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CARCINOGENESIS; CELL CYCLE ARREST; CLINICAL ARTICLE; DISEASE COURSE; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVATION; GENOME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

AGED; CARCINOMA; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; HISTONES; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA;

EID: 33749049326     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2006.08.026     Document Type: Article

References (45)

1. Garnick M.B., and Fair W.R. Prostate cancer: emerging concepts. Part I. Ann. Intern. Med. 125 (1996) 118-125
2. Coffey D.S. Prostate cancer. An overview of an increasing dilemma. Cancer 71 (1993) 880-886
3. Abate-Shen C., and Shen M.M. Molecular genetics of prostate cancer. Genes Dev. 14 (2000) 2410-2434
4. Myers R.B., Srivastava S., Oelschlager D.K., and Grizzle W.E. Expression of p160erbB-3 p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. Natl. Cancer Inst. 86 (1994) 1140-1145
5. Meng T.C., and Lin MF M.F. Tyrosine phosphorylation of c-ErbB-2 is regulated by the cellular form of prostatic acid phosphatase in human prostate cancer cells. J. Biol. Chem. 273 (1998) 22096-22104
6. Craft N., Shostak Y., Care M., and Sawyers C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5 (1999) 280-285
7. Graff J.R., Konicek B.W., McNulty A.M., Wang Z., Houck K., Allen S., Paul J.D., Hbaiu A., Goode R.G., Sandusky G.E., Vessella R.L., and Neubauer B.L. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Biol. Chem. 275 (2000) 24500-24505
8. Persad S., Attwell S., Gray V., Delcommenne M., Troussard A., Sanghera J., and Dedhar S. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3207-3212
9. Bowen C., Bubendorf L., Voeller H.J., Slack R., Willi N., Sauter G., Gasser T.C., Koivisto P., Lack E.E., Kononen J., Kallioniemi O.P., and Gelmann E.P. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 60 (2000) 6111-6115
10. Kim M.J., Cardiff R.D., Desai N., Banach-Petrosky W.A., Parson R., Shen M.M., and Abate-Shen C. Cooperativity of Nkx3.1 and pTEN loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 2884-2889
11. Narla G., Heath K.E., Reeves H.L., Li D., Giono L.E., Kimmelman A.C., Glucksman M.J., Narla J., Eng F.J., Chan A.M., Ferrari A.C., Martignetti J.A., and Friedman S.L. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294 (2001) 2563-2566
12. Furuya Y., Lin X.S., Walsh J.C., Nelson W.G., and Isaacs J.T. Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinology 136 (1995) 1898-1906
13. Guo Y., Sklar G.N., Borkowski A., and Kyprianou N. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin. Cancer Res. 3 (1997) 2269-2274
14. Macri E., and Loda M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev. 17 (1998) 337-444
15. Tsihlias J., Kapusta L.R., DeBoer G., Morava-Protzner I., Zbieranowski I., Bhattacharya N., Catzavelos G.C., Klotz L.H., and Slingerland J.M. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 58 (1998) 542-548
16. Besson A., Robbins S.M., and Yong V.W. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur. J. Biochem. 263 (1999) 605-611
17. Cantley L.C., and Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4240-4245
18. Di Cristofano A., and Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell 100 (2000) 387-390
19. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instabilities in human cancers. Nature 396 (1998) 643-649
20. Schar P. Spontaneous DNA damage, genome instability, and cancer-when DNA replication escapes control. Cell 104 (2001) 329-332
21. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 411 (2001) 366-374
22. Rouse J., and Jackson S.P. Interfaces between the detection, signaling, and repair of DNA damage. Science 297 9 (2002) 547-551
23. Zhou B.B., and Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 408 (2000) 433-439
24. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev., Cancer 3 (2003) 155-168
25. Bakkenist C.J., and Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421 (2003) 499-506
26. Lee J.H., and Paull T.T. Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science 304 (2004) 93-96
27. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat. Rev., Mol. Cell Biol. 2 (2001) 731-737
28. Li Y., Wu D., Chen B., Ingram A., He L., Liu L., Zhu D., Kapoor A., and Tang D. ATM activity contributes to the tumor-suppressing functions of p14ARF. Oncogene 23 (2004) 7355-7365
29. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio R.A., Kastrinakis Jr. N.G., Levy B., Kletsas D., Yoneta A., Herlyn M., Kittas C., and Halazonetis T.D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434 (2005) 907-913
30. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., Orntoft T., Lukas J., and Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005) 864-870
31. Gleason D.F., and Mellinger G.T. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M. (Ed). Urologic Pathology: The Prostate (1998), Lea and Febiger, Philadelphia 171-198
32. Lavin M.F. An unlikely player joins the ATM signalling network. Nat. Cell Biol. 2 (2000) E215-E217
33. McDonnell T.J., Troncoso P., Brisbay S.M., Logothetis C., Chung L.W., Hsieh J.T., Tu S.M., and Campbell M.L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52 (1992) 6940-6944
34. Colombel M., Symmans F., Gil S., O'Toole K.M., Chopin D., Benson M., Olsson C.A., Korsmeyer S., and Buttyan R. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am. J. Pathol. 143 (1993) 390-400
35. Lu Q.L., Abel P., Foster C.S., and Lalani E.N. bcl-2: role in epithelial differentiation and oncogenesis. Hum. Pathol. 27 (1996) 102-110
36. Stattin P., Damber J.E., Karlberg L., Nordgren H., and Bergh A. Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol. Res. 24 (1996) 257-264
37. Youn C.K., Cho H.J., Kim S.H., Kim H.B., Kim M.H., Chang I.Y., Lee J.S., Chung M.H., Hahm K.S., and You H.J. Bcl-2 expression suppresses mismatch repair activity through inhibition of E2F transcriptional activity. Nat. Cell Biol. 7 (2005) 137-147
38. Cortez D., Wang Y., Qin J., and Elledge S.J. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286 (1999) 1162-1166
39. Zhou B.B., Chaturvedi P., Spring K., Scott S.P., Johanson R.A., Mishra R., Mattern M.R., Winkler J.D., and Khanna K.K. Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J. Biol. Chem. 275 (2000) 10342-10348
40. Thompson D., and Easton D.F. Breast cancer linkage consortium. Cancer incidence in BRCA1 mutation carriers. J. Natl. Cancer Inst. 94 (2002) 1358-1365
41. Dong X., Wang L., Taniguchi K., Wang X., Cunningham J.M., McDonnell S.K., Qian C., Marks A.F., Slager S.L., Peterson B.L., Smith D.L., Cheville J.C., Blute M.L., Jacobsen S.J., Schaid D.J., Tindall D.J., Thibodeau S.N., and Liu W. Mutations in CHEK2 associated with prostate cancer risk. Am. J. Hum. Genet. 72 (2003) 270-280
42. Seppala E.H., Ikonen T., Mononen N., Autio V., Rokman A., Matikainen M.P., Tammela T.L., and Schleutker J. CHEK2 variants associate with hereditary prostate cancer. Br. J. Cancer 89 (2003) 1966-1970
43. Angele S., Falconer A., Edwards S.M., Dork T., Bremer M., Moullan N., Chapot B., Muir K., Houlston R., Norman A.R., Bullock S., Hope Q., Meitz J., Dearnaley D., Dowe A., Southgate C., Ardern-Jones A., Easton D.F., Eeles R.A., and Hall J. ATM polymorphisms as risk factors for prostate cancer development. Br. J. Cancer 91 (2004) 783-787
44. Wagenius M., Borg A., Johansson L., Giwercman A., and Bratt O. CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden. Scand. J. Urol. Nephrol. 40 (2006) 23-25
45. Angele S., Falconer A., Foster C.S., Taniere P., Eeles R.A., and Hall J. ATM protein overexpression in prostate tumors: possible role in telomere maintenance. Am. J. Clin. Pathol. 121 (2004) 231-236